Markers of the inflammatory response, interleukin 6, C-reactive protein, albumin and full blood count, were measured in non-small-cell lung cancer (NSCLC) patients (n=21) with and without weight loss (>5%). There were significant increases in circulating C-reactive protein (P<0.001), interleukin 6 (P<0.01) and platelets (P<0.01) in the weight-losing group. Moreover, there was a statistically significnt correlation (r=0.785, P<0.001) between interleukin 6 and C-reactive protein concentrations. These results are consistent with interleukin 6 and the acute phase response promoting weight loss in NSCLC.
Lung cancer, of which non-small-cell lung cancer (NSCLC) constitutes about 80%, is the greatest cause of cancer-related death worldwide. It presents late with advanced incurable disease for which treatment options are limited (Splinter, 1991) . Weight loss is a common symptom in patients with non-small-cell lung cancer and significantly associated with poor prognosis in such patients (Sridhar et al., 1990; Ihde and Minna, 1991; Thorogood et al., 1992; Espinosa et al., 1995) .
It has been proposed that mediators of the acute phase response (produced by the host in response to the tumour) are important in promoting weight loss in cancer patients (Fearon, 1992) . For example, animal work suggests a major role for interleukin 6 in cancer cachexia (Strassman et al., 1992) . Indeed, in humans interleukin 6 appears to be a primary regulator of the acute phase response (Heinrich et al., 1990) . Furthermore, reports have documented an increase in circulating interleukin 6 concentrations in gastrointestinal cancer (Fearon et al., 1991; Falconer et al., 1994b) and lung cancer patients (Yanagawa et al., 1995) .
We present preliminary data describing the relationship between weight loss, interleukin 6 and the acute phase response in patients with NSCLC.
Materials and methods
Patients (n=21) who, within the previous 12 months, had either none or more than 5% weight loss were studied. All patients had cytologically or histologically confirmed NSCLC and had (P<0.01) in the weight-losing group. There were also increases in white blood cell and neutrophil counts which approached statistical significance at the 5% level.
In the weight-losing group we examined the relationship between the rate of weight loss and the circulating concentrations of interleukin 6 and C-reactive protein. In this small group (n = 12) there were no significant correlations between the rate of weight loss and C-reactive protein or interleukin 6. There was a statistically significant Spearman rank correlation (r=0.785, P<0.001) between interleukin 6 and C-reactive protein concentrations in both patient groups.
The present study demonstrates for the first time, in NSCLC patients, the relationship between weight loss and the acute phase response. The circulating concentrations of interleukin 6 were consistently higher in the group with at least 5% weight loss compared with the group without weight loss. Recent animal work (Strassman et al., 1992; Ohe et al., 1993) indicates that interleukin 6 has a pivotal role in the development of cancer cachexia. The circulating concentrations of interleukin 6 were consistently higher in the group with at least 5% weight loss compared with the group without weight loss. This suggests that interleukin 6 may have a role in the development of cachexcia in these patients.
In the patients studied there was a statistically significant correlation between circulating concentrations of interleukin 6 and C-reactive protein (P<0.0O1). These results are consistent with the role of interleukin 6 as a primary mediator of the acute phase protein response. The presence of a more active acute phase response in the weight-losing group was confirmed by the increased circulating white blood cell and neutrophil counts.
It has been reported that administration of recombinant human interleukin 6 increases the number of circulating platelets in primates (Mayer et al., 1991) . This is consistent with the findings of the present study in which an increase in platelet count in the weight-losing group (P<0.01) was associated with an increase in interleukin 6 concentrations. In contrast, Yanagawa and coworkers (1995) have reported no increase in blood platelet counts associated with increased interleukin 6 concentrations in lung cancer patients. However, unlike the present study several tumour types (including small-cell carcinoma) were studied and this may have been a confounding factor.
The mechanisms by which the on-going acute phase response may promote weight loss in cancer have not been fully elucidated. However, there is evidence that the associated alterations in fat, protein and energy metabolism (Selberg et al., 1990; Fearon et al., 1991; McMillan et al., 1994; Falconer et al., 1994a) are detrimental to the patient and may contribute to reduced survival .
It has been reported recently that ibuprofen (a nonsteroidal anti-inflammatory agent) can moderate protein synthesis, energy expenditure and circulating interleukin 6 concentrations in cancer patients with an acute phase response Wigmore et al., 1995; . These studies together with the present study suggest a potential role for non-steroidal antiinflammatory agents such as ibuprofen in the treatment of weight loss in NSCLC.
